| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 20 | 2012 | 3168 | 1.320 |
Why?
|
| Cyclin D1 | 6 | 2009 | 576 | 0.940 |
Why?
|
| NF-kappa B | 7 | 2009 | 1549 | 0.840 |
Why?
|
| Adenocarcinoma | 20 | 2013 | 7789 | 0.590 |
Why?
|
| Biomarkers, Tumor | 13 | 2015 | 10331 | 0.530 |
Why?
|
| Hedgehog Proteins | 7 | 2013 | 424 | 0.510 |
Why?
|
| Precancerous Conditions | 8 | 2009 | 1058 | 0.450 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 1450 | 0.380 |
Why?
|
| Gene Expression Profiling | 5 | 2015 | 5159 | 0.270 |
Why?
|
| Cyclooxygenase 2 | 1 | 2007 | 483 | 0.260 |
Why?
|
| Barrett Esophagus | 2 | 2008 | 569 | 0.250 |
Why?
|
| Immunohistochemistry | 13 | 2013 | 7548 | 0.250 |
Why?
|
| Carcinoma | 2 | 2006 | 2578 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2011 | 4549 | 0.240 |
Why?
|
| Genomic Instability | 1 | 2007 | 519 | 0.240 |
Why?
|
| Laryngeal Neoplasms | 2 | 2009 | 518 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2014 | 2488 | 0.220 |
Why?
|
| Chemoradiotherapy | 1 | 2011 | 1946 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2012 | 8873 | 0.200 |
Why?
|
| Gene Amplification | 2 | 2005 | 731 | 0.190 |
Why?
|
| Mouth Neoplasms | 2 | 2003 | 713 | 0.180 |
Why?
|
| ras Proteins | 2 | 2014 | 770 | 0.180 |
Why?
|
| Genes, ras | 3 | 2008 | 667 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2011 | 15862 | 0.170 |
Why?
|
| Bile Acids and Salts | 3 | 2013 | 246 | 0.170 |
Why?
|
| Lung Neoplasms | 6 | 2015 | 11538 | 0.170 |
Why?
|
| Fluorouracil | 5 | 2011 | 1944 | 0.160 |
Why?
|
| Stomach Neoplasms | 2 | 2007 | 2278 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5319 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2009 | 5437 | 0.150 |
Why?
|
| Fibroblast Growth Factors | 1 | 1998 | 257 | 0.150 |
Why?
|
| Disease Progression | 6 | 2007 | 6682 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2011 | 5178 | 0.130 |
Why?
|
| Combined Modality Therapy | 9 | 2009 | 8865 | 0.130 |
Why?
|
| Esophagectomy | 3 | 2008 | 911 | 0.130 |
Why?
|
| Vinblastine | 2 | 1994 | 453 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 5539 | 0.130 |
Why?
|
| Anus Neoplasms | 2 | 2009 | 411 | 0.120 |
Why?
|
| Humans | 46 | 2015 | 261506 | 0.120 |
Why?
|
| Disease-Free Survival | 4 | 2011 | 10001 | 0.120 |
Why?
|
| Aurora Kinases | 2 | 2011 | 189 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 5 | 2005 | 3976 | 0.120 |
Why?
|
| Colonic Neoplasms | 3 | 2013 | 1390 | 0.110 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2014 | 132 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2010 | 6207 | 0.110 |
Why?
|
| Aurora Kinase A | 2 | 2011 | 202 | 0.110 |
Why?
|
| Treatment Outcome | 10 | 2011 | 32848 | 0.110 |
Why?
|
| Protein Kinases | 2 | 2008 | 874 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2008 | 1823 | 0.100 |
Why?
|
| Signal Transduction | 8 | 2013 | 11965 | 0.100 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 336 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 131 | 0.100 |
Why?
|
| Cisplatin | 4 | 2011 | 2432 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2012 | 1546 | 0.100 |
Why?
|
| Colonic Polyps | 1 | 2013 | 209 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 376 | 0.100 |
Why?
|
| Prognosis | 8 | 2013 | 21713 | 0.100 |
Why?
|
| Female | 22 | 2014 | 141928 | 0.090 |
Why?
|
| Sulfones | 2 | 2008 | 143 | 0.090 |
Why?
|
| Antineoplastic Agents | 9 | 2010 | 14289 | 0.090 |
Why?
|
| Cell Communication | 1 | 2013 | 509 | 0.090 |
Why?
|
| Middle Aged | 16 | 2014 | 86204 | 0.090 |
Why?
|
| Disease Management | 1 | 2015 | 1052 | 0.090 |
Why?
|
| Colon | 1 | 2013 | 670 | 0.090 |
Why?
|
| Ki-67 Antigen | 2 | 2009 | 666 | 0.090 |
Why?
|
| Neoplasm Proteins | 3 | 2007 | 3230 | 0.090 |
Why?
|
| Lignans | 1 | 2009 | 15 | 0.090 |
Why?
|
| Male | 19 | 2014 | 123000 | 0.090 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 591 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2005 | 2232 | 0.090 |
Why?
|
| Laryngeal Diseases | 1 | 2009 | 49 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2009 | 172 | 0.080 |
Why?
|
| Fenretinide | 1 | 2009 | 96 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2009 | 641 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2009 | 185 | 0.080 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 129 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 1399 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2006 | 3981 | 0.080 |
Why?
|
| Proteomics | 1 | 2015 | 1380 | 0.080 |
Why?
|
| Aged | 13 | 2011 | 70117 | 0.080 |
Why?
|
| Biphenyl Compounds | 1 | 2009 | 194 | 0.080 |
Why?
|
| alpha-Tocopherol | 2 | 2009 | 78 | 0.080 |
Why?
|
| Adult | 13 | 2014 | 77950 | 0.080 |
Why?
|
| Multigene Family | 2 | 2007 | 425 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2009 | 402 | 0.080 |
Why?
|
| Isotretinoin | 2 | 2009 | 158 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2012 | 2054 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2015 | 2086 | 0.070 |
Why?
|
| Radiation Tolerance | 2 | 2008 | 629 | 0.070 |
Why?
|
| Guanine | 1 | 2007 | 151 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 2483 | 0.070 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 204 | 0.070 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2006 | 74 | 0.070 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2006 | 56 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2009 | 6869 | 0.070 |
Why?
|
| Genotype | 4 | 2010 | 4109 | 0.070 |
Why?
|
| Telomere | 1 | 2009 | 505 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2007 | 298 | 0.070 |
Why?
|
| Chemoprevention | 1 | 2007 | 241 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2013 | 13658 | 0.070 |
Why?
|
| Carrier Proteins | 2 | 2009 | 2022 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2007 | 587 | 0.070 |
Why?
|
| Esophagus | 1 | 2009 | 553 | 0.070 |
Why?
|
| Infusions, Intravenous | 3 | 2006 | 1382 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 327 | 0.070 |
Why?
|
| Metaplasia | 1 | 2007 | 383 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 1 | 2007 | 152 | 0.070 |
Why?
|
| Esophagoscopy | 1 | 2007 | 291 | 0.070 |
Why?
|
| Zinc Finger Protein GLI1 | 3 | 2012 | 111 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2005 | 476 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2008 | 1529 | 0.060 |
Why?
|
| Probability | 1 | 2007 | 866 | 0.060 |
Why?
|
| Centrosome | 1 | 2005 | 95 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 573 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2008 | 419 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 4 | 2007 | 3203 | 0.060 |
Why?
|
| Sirolimus | 2 | 2008 | 814 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 5 | 2008 | 5395 | 0.060 |
Why?
|
| Genomics | 1 | 2015 | 2738 | 0.060 |
Why?
|
| Recurrence | 2 | 2011 | 4758 | 0.060 |
Why?
|
| Chromosomal Instability | 1 | 2005 | 233 | 0.060 |
Why?
|
| Pulmonary Alveoli | 1 | 2005 | 208 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2009 | 2359 | 0.060 |
Why?
|
| Adenine | 1 | 2007 | 631 | 0.060 |
Why?
|
| Thymidylate Synthase | 2 | 2001 | 53 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 986 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2014 | 2819 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 4971 | 0.060 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2010 | 962 | 0.060 |
Why?
|
| Interferon-alpha | 2 | 2009 | 889 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 1866 | 0.060 |
Why?
|
| Camptothecin | 1 | 2006 | 517 | 0.060 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2003 | 176 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 1363 | 0.050 |
Why?
|
| Indoles | 1 | 2008 | 1009 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 4988 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 1678 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 2 | 2013 | 5061 | 0.050 |
Why?
|
| Taxoids | 1 | 2006 | 967 | 0.050 |
Why?
|
| RNA, Small Interfering | 4 | 2009 | 2216 | 0.050 |
Why?
|
| Cadherins | 1 | 2005 | 660 | 0.050 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2001 | 20 | 0.050 |
Why?
|
| DNA Repair | 1 | 2009 | 1872 | 0.050 |
Why?
|
| Folic Acid Antagonists | 1 | 2001 | 45 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2001 | 974 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2014 | 37905 | 0.050 |
Why?
|
| Radiotherapy | 4 | 2009 | 1824 | 0.050 |
Why?
|
| Cyclins | 1 | 2001 | 456 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2007 | 5112 | 0.040 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 1998 | 22 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2003 | 649 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2012 | 5270 | 0.040 |
Why?
|
| Cell Cycle Proteins | 2 | 2005 | 2045 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3890 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2010 | 2341 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2008 | 9244 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1998 | 181 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 2508 | 0.040 |
Why?
|
| Cell Line, Tumor | 5 | 2013 | 14551 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 1331 | 0.040 |
Why?
|
| Leukoplakia, Oral | 1 | 1997 | 70 | 0.040 |
Why?
|
| Lung | 1 | 2008 | 3151 | 0.040 |
Why?
|
| Idoxuridine | 1 | 1996 | 17 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2009 | 1165 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2010 | 1053 | 0.030 |
Why?
|
| Mutation | 2 | 2014 | 15179 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2007 | 9180 | 0.030 |
Why?
|
| Blotting, Western | 3 | 2008 | 3536 | 0.030 |
Why?
|
| Transfection | 2 | 2013 | 2944 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2001 | 1299 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 1996 | 371 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1998 | 1064 | 0.030 |
Why?
|
| Mustard Compounds | 1 | 2013 | 8 | 0.030 |
Why?
|
| Thyroid Nodule | 1 | 2014 | 92 | 0.030 |
Why?
|
| Phenylpropionates | 1 | 2013 | 19 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 3639 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1998 | 1005 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2013 | 260 | 0.030 |
Why?
|
| Animals | 8 | 2013 | 59536 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2007 | 3821 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 328 | 0.030 |
Why?
|
| Cell Proliferation | 3 | 2012 | 7226 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2012 | 4804 | 0.030 |
Why?
|
| Mice | 6 | 2013 | 34495 | 0.030 |
Why?
|
| Vindesine | 1 | 1990 | 11 | 0.020 |
Why?
|
| Osteonectin | 1 | 2010 | 53 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 690 | 0.020 |
Why?
|
| Cell Division | 2 | 2008 | 2489 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 837 | 0.020 |
Why?
|
| Osteopontin | 1 | 2010 | 148 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2010 | 6100 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 460 | 0.020 |
Why?
|
| Cyclophilins | 1 | 2009 | 32 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 4757 | 0.020 |
Why?
|
| Remission Induction | 3 | 2008 | 3569 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2013 | 825 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2009 | 69 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 1489 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 394 | 0.020 |
Why?
|
| DNA Methylation | 2 | 2013 | 2669 | 0.020 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2008 | 21 | 0.020 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2008 | 51 | 0.020 |
Why?
|
| Anal Canal | 1 | 2009 | 238 | 0.020 |
Why?
|
| Endonucleases | 1 | 2009 | 178 | 0.020 |
Why?
|
| Apoptosis | 3 | 2008 | 7591 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2003 | 12873 | 0.020 |
Why?
|
| Neoplasms | 2 | 2007 | 15193 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 973 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2009 | 343 | 0.020 |
Why?
|
| Introns | 1 | 2009 | 432 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 237 | 0.020 |
Why?
|
| BCG Vaccine | 1 | 2010 | 399 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 717 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2013 | 1026 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 644 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1099 | 0.020 |
Why?
|
| Trans-Activators | 2 | 2007 | 1555 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2009 | 521 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2007 | 205 | 0.020 |
Why?
|
| Chemokine CXCL2 | 1 | 2006 | 35 | 0.020 |
Why?
|
| Mice, Nude | 2 | 2006 | 4307 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2006 | 60 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 760 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2009 | 3842 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 117 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 1062 | 0.020 |
Why?
|
| Informed Consent | 1 | 2009 | 419 | 0.020 |
Why?
|
| Biological Transport | 1 | 2007 | 597 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1992 | 1039 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 299 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2007 | 354 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 2005 | 67 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2008 | 334 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2005 | 116 | 0.020 |
Why?
|
| Chemokines | 1 | 2006 | 314 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2005 | 202 | 0.020 |
Why?
|
| Drug Administration Schedule | 3 | 1998 | 3472 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2012 | 1664 | 0.010 |
Why?
|
| Endosonography | 1 | 2007 | 536 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 287 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 3719 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 14889 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2005 | 557 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2005 | 311 | 0.010 |
Why?
|
| Nitriles | 1 | 2008 | 906 | 0.010 |
Why?
|
| Ligands | 1 | 2006 | 995 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 4298 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 6086 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1992 | 1429 | 0.010 |
Why?
|
| Models, Biological | 1 | 2012 | 3254 | 0.010 |
Why?
|
| Base Sequence | 1 | 2009 | 4917 | 0.010 |
Why?
|
| RNA Interference | 1 | 2006 | 1408 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 534 | 0.010 |
Why?
|
| Cyclin D | 1 | 2001 | 37 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2009 | 1818 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 1764 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2008 | 1996 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2007 | 2084 | 0.010 |
Why?
|
| DNA-Binding Proteins | 2 | 2009 | 4821 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2010 | 10035 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2001 | 231 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2001 | 256 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2005 | 3552 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 1996 | 3578 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2001 | 290 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 3570 | 0.010 |
Why?
|
| Adenoma | 1 | 2005 | 716 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2006 | 1048 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 575 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 602 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2001 | 369 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1996 | 4557 | 0.010 |
Why?
|
| Karyotyping | 1 | 2001 | 1022 | 0.010 |
Why?
|
| Anticarcinogenic Agents | 1 | 2001 | 362 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 1994 | 15694 | 0.010 |
Why?
|
| Survival Rate | 2 | 2008 | 12221 | 0.010 |
Why?
|
| DCC Receptor | 1 | 1998 | 14 | 0.010 |
Why?
|
| Risk Factors | 2 | 2009 | 17523 | 0.010 |
Why?
|
| Phosphoribosyl Pyrophosphate | 1 | 1998 | 6 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2007 | 1225 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 5710 | 0.010 |
Why?
|
| Neutropenia | 2 | 1994 | 968 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1998 | 4938 | 0.010 |
Why?
|
| Inflammation | 1 | 2008 | 2522 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 1998 | 89 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 2049 | 0.010 |
Why?
|
| Nucleotides | 1 | 1998 | 164 | 0.010 |
Why?
|
| Thiophenes | 1 | 1998 | 148 | 0.010 |
Why?
|
| Smad4 Protein | 1 | 1998 | 196 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 2809 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1996 | 62 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1992 | 4638 | 0.010 |
Why?
|
| Cell Death | 1 | 1998 | 671 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1998 | 771 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1998 | 577 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 1996 | 240 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1996 | 660 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1998 | 1313 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1994 | 231 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 1471 | 0.010 |
Why?
|
| Point Mutation | 1 | 1997 | 769 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 862 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2001 | 1960 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1997 | 1643 | 0.010 |
Why?
|
| DNA | 1 | 2001 | 2693 | 0.010 |
Why?
|
| Quinazolines | 1 | 1998 | 923 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1997 | 1910 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 12926 | 0.010 |
Why?
|
| Radiometry | 1 | 1996 | 980 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1990 | 425 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 4053 | 0.010 |
Why?
|
| Biopsy | 1 | 1997 | 3443 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1990 | 684 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1996 | 2358 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1990 | 479 | 0.000 |
Why?
|
| Liver | 1 | 1996 | 2961 | 0.000 |
Why?
|